These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6131962

  • 1. Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs.
    Macgregor TR, Drum MA, Harrigan SE, Wiley JN, Reuning RH.
    J Pharm Pharmacol; 1983 Jan; 35(1):38-42. PubMed ID: 6131962
    [Abstract] [Full Text] [Related]

  • 2. Metabolic reduction of naltrexone. I. Synthesis, separation and characterization of naloxone and naltrexone reduction products and qualitative assay of urine and bile following administration of naltrexone, alpha-naltrexol, or beta-naltrexol.
    Malspeis L, Bathala MS, Ludden TM, Bhat HB, Frank SG, Sokoloski TD, Morrison BE, Reuning RH.
    Res Commun Chem Pathol Pharmacol; 1975 Sep; 12(1):43-65. PubMed ID: 810832
    [Abstract] [Full Text] [Related]

  • 3. Elimination of radioactivity following administration of [15,16-3H]naltrexone to rats and guinea pigs.
    Ludden TM, Bathala MS, Malspeis L, Drum MA, Reuning RH.
    Drug Metab Dispos; 1978 Sep; 6(3):321-8. PubMed ID: 26554
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.
    Dayton HE, Inturrisi CE.
    Drug Metab Dispos; 1976 Sep; 4(5):474-8. PubMed ID: 10147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tritiated naltrexone binding in plasma from several species and tissue distribution in mice.
    Ludden TM, Malspeis L, Baggot JD, Sokoloski TD, Frank SG, Reuning RH.
    J Pharm Sci; 1976 May; 65(5):712-6. PubMed ID: 819644
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH, Malspeis L, Frank S, Notari RE.
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):43-5. PubMed ID: 823438
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic quantitation of naltrexone release from several sustained-release delivery systems.
    Reuning RH, Liao SH, Staubus AE.
    NIDA Res Monogr; 1981 Jan; 28():172-84. PubMed ID: 6791003
    [Abstract] [Full Text] [Related]

  • 15. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.
    Verebey K, Volavka J, Mulé SJ, Resnick RB.
    Clin Pharmacol Ther; 1976 Sep; 20(3):315-28. PubMed ID: 954353
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system.
    Reuning RH, Liao SH, Staubus AE, Ashcraft SB, Downs DA, Harrigan SE, Wiley JN, Wise DL.
    J Pharmacokinet Biopharm; 1983 Aug; 11(4):369-87. PubMed ID: 6422028
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Kinetics of a naltrexone sustained-release preparation.
    Chiang CN, Hollister LE, Kishimoto A, Barnett G.
    Clin Pharmacol Ther; 1984 Nov; 36(5):704-8. PubMed ID: 6488691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.